The article may have been published today but, it seems the author hadn't checked the pps recently:
The company currently trades at $0.50 per share, and we expect it to increase in share price in 2014.
I'm not sure the author presented anything "new." It seems that a number of known points were simply "recycled" from various other sources.
This is true:
If the platform proves to be successful in a final clinical outcome in phase 3 then this small cap biotechnology company will for sure be a game changer in the biotech industry.